TNFRSF12A and renal carcinoma: Enavatuzumab showed potent tumor cell killing on all TweakR-positive tumor cells tested, including the renal carcinoma cell line SN12C, the melanoma cell line A375, and the colorectal cancer cell lines HCT116 and DLD-1 (Figure 1(a)).